SEC Comment Letter for Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Nov 30, 2012
Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: Nov. 30, 2012 · CIK: 0001541157 · Accession: 0000000000-12-064751
AI Filing Summary & Sentiment
Show Raw Text
November 29, 2012 Via E -mail Dr. Yuval Cohen President Morria Biopharmaceuticals PLC 53 Davies Street London W1K 5JH United Kingdom Re: Morria Biopharmaceuticals PLC Registration Statement on Form 20 -F Filed August 31 , 2012 File No. 000 -54749 Dear Dr. Cohen: We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey P. Riedler Jeffrey P. Riedler Assistant Di rector cc: Jeffrey Schultz, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 666 Third Avenue New York, NY 10017